anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pregnancy Category C

Risk Summary

There are no adequate and well-controlled studies of Ca-DTPA use in pregnant women. Ca-DTPA chelation therapy causes depletion of body stores of zinc, a trace metal essential for fetal development [see Warnings and Precautions (5.2)]. The consequences of zinc depletion and results of animal studies suggest a teratogenic risk in humans. Ca-DTPA was teratogenic and embryotoxic in mice at daily doses 2 to 8 times the recommended daily human dose, based on body surface area (BSA), with a dose-dependent increase in the frequency of gross malformations. Ca-DTPA was teratogenic in dogs at approximately half the recommended daily human dose based on BSA, as described below. There are no animal or human data evaluating the teratogenic effect of a single dose of Ca-DTPA. Ca-DTPA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Clinical Considerations

Chelation treatment of pregnant women should begin and continue with Zn-DTPA, if available, except in cases of high internal radioactive contamination. Because Ca-DTPA is more effective than Zn-DTPA in the first 24 hours after internal contamination, it may be appropriate to use a single dose of Ca-DTPA with vitamin or mineral supplements that contain zinc as the initial treatment.

Animal Data

Ca-DTPA is teratogenic and embryotoxic in mice during any period of gestation following five daily subcutaneous injections of 720 to 2880 micromol Ca-DTPA/kg [2 to 8 times the recommended daily human dose of 1 gram based on BSA]. The frequency of gross malformations (e.g., exencephaly, spina bifida, cleft palate, ablepharia, and polydactyly) and fetal mortality increased with dose, with higher susceptibility in early and mid gestation. Five daily doses of 360 micromol Ca-DTPA/kg in mice, approximately equivalent to the recommended daily human dose (based on BSA) produced no harmful effects. A study of two pregnant dogs given daily intravenous injections of 30 micromol Ca-DTPA/kg (approximately half the recommended daily human dose based on BSA) from implantation until parturition showed severe teratogenic effects (brain damage), and decrease in the number of surviving pups.
CML-MBP has dismal outcome. Currently, there is no standardized induction treatment approach in CML-MBP. The European LeukemiaNet (ELN) recommendations and NCCN guideline recommended the combination of TKI and chemotherapy in CML-MBP. The previous study revealed that TKI combined with hypomethylating agents had promising efficacy. However, imatinib and second generation TKI are the most widely applied in combination treatment, there is limited data in third generation TKI.

Currently, venetoclax in combination with hypomethylating agents such as azacitidine is standard treatment for patients with AML unsuitable for intensive induction chemotherapy. Maiti et al. reported that TKI combined with venetoclax and detectable had promising efficacy in CML-MBP. Therefore, the investigator conducted a study to explore the efficacy and safety of a third generation TKI in combination with azacitidine and Bcl-2 inhibitor in CML-MBP and multi-omics exploratory analysis was performed to identify potential biomarkers correlated with the outcome.
Pharmacodynamics of Insulin Aspart After Subcutaneous Administration

The pharmacodynamic profile of Insulin Aspart given subcutaneously in 22 patients with type 1 diabetes is shown in Figure 2. The maximum glucose-lowering effect of Insulin Aspart occurred between 1 and 3 hours after subcutaneous injection (0.15 units/kg). The duration of action for Insulin Aspart is 3 to 5 hours. The time course of action of insulin and insulin analogs such as Insulin Aspart may vary considerably in different individuals or within the same individual. The parameters of Insulin Aspart activity (time of onset, peak time and duration) as designated in Figure 2 should be considered only as general guidelines. The rate of insulin absorption and onset of activity is affected by the site of injection, exercise, and other variables [see Warnings and Precautions ( 5.3)] . 

Pharmacodynamics of Insulin Aspart After Intravenous Administration

A double-blind, randomized, two-way crossover study in 16 patients with type 1 diabetes demonstrated that intravenous infusion of Insulin Aspart resulted in a blood glucose profile that was similar to that after intravenous infusion with regular human insulin. Insulin Aspart or human insulin was infused until the patient’s blood glucose decreased to 36 mg/dL, or until the patient demonstrated signs of hypoglycemia (rise in heart rate and onset of sweating), defined as the time of autonomic reaction (R) (see Figure 3).
Isolated nucleic acid molecules having a nucleotide sequence encoding canine pancreatic lipase polypeptides, allelic variants and fragments thereof. Vectors and host cells containing the polynucleotide sequences and methods for expressing the polypeptides. Monoclonal antibodies that specifically binds to the canine pancreatic lipase polypeptides. Cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of canine pancreatic lipase in a biological sample. The methods include using the monoclonal antibodies to specifically bind to canine pancreatic lipase polypeptides. The method includes using standards of recombinant canine pancreatic lipase. Devices and kits for performing methods for detecting canine pancreatic lipase in biological samples.
A system for reducing health-insurance costs including fraud for patients uses an identification card to allow doctors to obtain a patient's medical history. The identification card can either hold the medical history itself or can link the provider to a database containing the medical history. A method of using the card requires the card to be present to bill; this prevents fraud by the provider. A method of using the card requires the card to be matched to a photograph of the user; this prevents fraud by the card holder. The system includes a database of patients. According to a method, the database of patients can be monitored to check the frequency of diseases.
A fitness monitor comprises a housing, a wrist band, a motion sensor, a display, a non-transitory memory element and a processing element. The wrist band is coupled to the housing and configured to attach to a wrist of a user. The motion sensor is configured to sense motion of the user and generate motion data. The display is coupled to the housing and configured to present information associated with user activity. The memory element is located in the housing and configured to store the activity data and a daily activity goal. The processing element is operably coupled to the memory element and configured to determine daily activity data, a daily activity goal corresponding to a predetermined level of activity for the user, compute an activity countdown and level of inactivity, and present, on the display, the activity countdown and inactivity indicia indicating the level of inactivity.
We aim to evaluate the utility of continuous glucose monitors (CGMs) in improving the diagnosis and management of neonatal hypoglycemia in infants admitted to the neonatal intensive care unit (NICU). Specifically, we hope to assess whether the use of CGMs in this population reduces the number and severity of hypoglycemic events, reduces the time to diagnosis of the etiology of hypoglycemia and/or reduces the time taken to achieve stable euglycemia on a sustainable feeding regimen. We plan to perform a prospective pilot and feasibility study comparing the clinical course and outcomes of newborns with hypoglycemia admitted to the NICU who are actively monitored with CGMs versus those who receive routine care. Eligible infants will be late preterm and term infants admitted to the Boston Children's Hospital who have had two documented hypoglycemic episodes during their current admission. Families will be approached for consent shortly after diagnosis of recurrent hypoglycemia. As all of these infants will be undergoing periodic blood glucose monitoring as part of their routine care, enrollment in this study will involve minimal additional interventions, including CGM placement, which involves placement of a small subcutaneous needle sensor, and the possibility of drawing additional blood glucose samples if hypoglycemia is detected by CGM. All enrolled infants will be placed on a CGM monitor and then randomized to either the "CGM Protocol" or "Standard of Care" group. Those on the CGM Protocol will have a fully accessible CGM that will be analyzed for blood glucose trends and will alarm for any blood glucose level approaching hypoglycemic threshold (eg. BG \<70 mg/dL). Those in the "Standard of Care" group will have a CGM in place, but values will not be available to the clinical team except if severe hypoglycemia is recorded (eg. BG \<40 mg/dL). Whenever the CGM alarms or there is a concerning blood glucose trend as measured by the CGM, the nurse will be asked to check a blood glucose value. All clinical management decisions will be made by the clinical team based on confirmed blood glucose values. In the control group, the only change to current management is the potential performance of additional blood glucose checks that may be prompted by CGM alarms for severe hypoglycemia. The CGM will remain in place until the infant is no longer being monitored for glycemic stability or the infant is discharged. We will record all blood glucose levels, laboratory data related to investigation of the underlying cause of hypoglycemia, all intravenous and enteral sources of glucose, and uses of other therapeutic interventions such as diazoxide and carnitine replacement. We will also compare blood glucose data with information from the CGM monitors to assess accuracy. We will then compare severity and frequency of hypoglycemia, as well as times to diagnosis and euglycemia between the "CGM" and "Standard of Care" groups.
A family of cobalt based dental alloys suitable for PFM and SLM applications that do not exhibit ferromagnetism and that are capable of meeting the ADA requirements for a “noble” alloy are provided. The dental alloys comprise at least 25 wt. % of noble metals selected from either platinum alone or a combination of platinum and ruthenium, and from 23 to 32 wt. % chromium. Additional additive materials may be included in concentrations up to 3 wt. %. The ruthenium optionally comprises up to 8 wt. %, and in some embodiments from at least 5 wt. % to 8 wt. % of the noble metals such that the dental alloys are capable of meeting the ADA requirements for a “noble” alloy.
1,133,071. Purified gonadotropins. ORGANON LABORATORIES Ltd. 3 Jan., 1966 [15 Jan., 1965], No. 82/66. Heading A5B. Highly purified gonadotropins are prepared by chromatography by a process comprising contacting an aqueous solution of less pure gonadotropin concentrate with an ion-exchanging material comprising a cross-linked polysaccharide which also has the properties of a molecular sieve, e.g. carboxymethyl sephadex C25 and C50 and DEAE Sephadex A25 and A50 (Sephadex is a trade mark), and then eluting the active substances with at least one buffer solution, the material P having been washed with dilute acid prior to the equilibration with the buffer or starting buffer, and then separating the gonadotropins from the fractions obtained. Suitable buffer systems are sodium acetate-acetic acid, ammonium acetateacetic acid, pyridine-acetic acid, trimethylamine-acetic acid, triethylamine-acetic acid and salts of tris-(hydroxymethyl) aminomethane (tris). The buffer is preferably soluble in ethanol and at a concentration of 0.1 to 0.5 M. The ion-exchange material may be first swelled in distilled water, then washed with a dilute acid and then with distilled water and finally with the buffer solution to be applied. The gonadotropins may be further purified by gel filtration and separated from the eluate by lyophilisation. The starting material may be prepared by the process described in Specification 1132021.
BACKGROUND: Family-based behavioral treatment (FBT) is an effective intensive health behavior and lifestyle treatment for obesity reduction in children and adolescents, but families have limited access. The purpose of this randomized, pragmatic, comparative effectiveness trial was to examine changes in child relative weight in a 12-month, enhanced standard of care (eSOC) intervention combined with FBT (eSOC+FBT) vs. eSOC alone.
METHODS: Children aged 6 to 15 years with obesity, and their primary caregiver, were recruited from primary care clinics. Families were randomized 1:1 to eSOC, a staged approach led by the primary care provider that gradually intensified dependent on a child's response to care and aligns with the American Medical Association guidelines, or the eSOC+FBT arm, which included regular meetings with a health coach for healthy eating, physical activity, positive parenting strategies, and managing social and environmental cues. Both treatments align with the 2023 American Academy of Pediatrics clinical practice guidelines. Assessments occurred at baseline, midpoint (month 6), end-of-intervention (month 12), and follow-up (month 18). Primary outcome was change from baseline to 12 months in child percent overweight (percentage above the median body mass index in the general US population normalized for age and sex). Secondary outcomes were parent weight, child psychosocial factors, heterogeneity of treatment effects, and cardiometabolic risk factors. Exploratory outcomes assessed reach, effectiveness, adoption, implementation, and maintenance.
CONCLUSION: This pragmatic trial will generate evidence for the comparative effectiveness of implementing two guidelines-based approaches in primary care for obesity reduction in children and adolescents.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03843424.
FIELD: organic chemistry, medicine, neurology. SUBSTANCE: invention relates to group of compounds of the general formula (I) of high purity degree:   where Q represents group of positive charge taken among amido-groups or groups of the formula XYN- where X and Y are similar or different and each can represents hydrogen atom, C 1 -C 6 -alkyl or a simple group comprising heteroatom, or in common with nitrogen atom to which they are linked form heterocyclic group with nitrogen atom; R a  represents linear or branched alkylene chain or alkylene group comprising from 1 to 6 carbon atoms and each of that is substituted selectively with from 1 to 4 alkyl groups comprising from 1 to 3 carbon atoms; R       b   1        R c  both represent alkylene or alkylene group comprising 3 or 4 carbon atoms in linear chain each of that can be substituted selectively with 1 or 2 alkyl groups each of that comprises from 1 to 3 carbon atoms in the total number of carbon atoms 7 in indicated linear chains of R b  and R c ; R 2  and R 3  are similar or differ each of other and each represents hydrogen atom of the formula R, RCO-, ROCO- or RNHCO- where R represents alkyl or aryl group being indicated groups can be substituted selectively with one or more number of substituents α determined below; chiral carbon atom designated by asterisk in  -configuration; Z is an amino acid aromatic residue; n = 0 or 1; R 1  represents hydrogen atom or smaller alkyl group that can be substituted selectively with one or more number of substituents α determined below; W represents hydrogen atom or alkyl or aryl group; substituents αz are taken among halogens atoms, amino-groups, alkylamino-groups, dialkylamino- groups, cyano-groups, hydroxyls, alkyl groups (with exception of cases with substitution of alkyl), aryl groups, carbamyl groups, alkyl- and dialkylcarbamyl groups and carboxyl groups and derivatives of latter as esters. Invention relates also to pharmaceutically acceptable salts of compound where the most long chain of compound (except for hydrogen atoms) comprises from 14 to 25 and these compounds elicit neuroprotective effect. Invention relates also to method of treatment of mammals to protect them from neuronal damages. EFFECT: valuable medicinal properties of compounds. 18 cl, 7 tbl, 4 dwg
The invention concerns RGS protein 17 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases and a variety of inflammations utilizing the polypeptide are disclosed. The invention discloses the antagonist agaisnt the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes RGS protein 17.
<P>PROBLEM TO BE SOLVED: To provide a composition for medical treatments that performs a function of positively accelerating healing of an intractable wound and promotes vascularization and tissue regeneration without a risk of causing side effects such as cancerization.  <P>SOLUTION: The composition for medical treatments comprises a hydrogel formed from a sugar chain-containing chitosan derivative and an acidic polysaccharide and, carried thereon, a drug for promoting healing of wounds. Preferably, the sugar chain-containing chitosan derivative is one obtained by incorporating a saccharide having a reducing end into at least a part of amino groups of a chitosan skeleton. Preferably, the acidic polysaccharide is a glycosaminoglycan such as periodic acid-oxidized heparin. Preferably, the drug for promoting healing of wounds is a cell growth factor.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Vascular toxicities coincident with the use of cisplatin in combination with other antineoplastic agents have been reported. The events are clinically heterogeneous and may include myocardial infarction, cerebrovascular accident, thrombotic microangiopathy (hemolytic-uremic syndrome [HUS]), or cerebral arteritis. Various mechanisms have been proposed for these vascular complications. There are also reports of Raynaud’s phenomenon occurring in patients treated with the combination of bleomycin, vinblastine with or without cisplatin. It has been suggested that hypomagnesemia developing coincident with the use of cisplatin may be an added, although not essential, factor associated with this event. However, it is currently unknown if the cause of Raynaud’s phenomenon in these cases is the disease, underlying vascular compromise, bleomycin, vinblastine, hypomagnesemia, or a combination of any of these factors.
INTRODUCTION: The role and impact of preoperative chemotherapy (PC) in pancreatic adenocarcinoma are questions under active investigation. Here we investigate the rate of failure to rescue (FTR) and surgical outcomes in patients undergoing pancreatectomy, with PC within 90 days (d) prior to surgery and without PC.
MATERIALS AND METHODS: The National Surgical Quality Improvement Program Targeted Dataset for Pancreatectomy (2014-2020) was queried to identify patients who underwent pancreatectomy for malignant non-neuroendocrine pancreatic tumors. The cohort was divided into those who underwent PC within 90 d and those without. Propensity score analysis was employed to match patients 1:1 based on age, sex, body mass index, hypertension, smoking status, ascites, diabetes, and American Society of Anesthesiology (ASA) score. The primary outcome of interest was FTR, defined as mortality following a major complication (Clavien-Dindo Class III-V).
RESULTS: After propensity score matching, 7895 patients with PC were matched to 7895 patients without PC. PC patients exhibited a significantly lower rate of FTR (P = 0.002) despite having higher ASA scores. This benefit was most pronounced in the pancreaticoduodenectomy subgroup (P < 0.009). PC patients demonstrated a lower rate of overall complications compared to those without PC (P < 0.001). Overall, the PC group was more likely to require vascular resection (P < 0.001).
CONCLUSIONS: Patients who received chemotherapy within 90 d prior to surgery experienced a lower rate of FTR and overall complications despite higher ASA scores and incidence of vascular resection. This suggests that, when appropriate, the receipt of PC does not negatively impact surgical outcomes.
PURPOSE: A composition for treating atopic dermatitis containing various herb extracts is provided to ensure antibacterial, anti-inflammation, and anti-oxidation. CONSTITUTION: A composition for treating atopic dermatitis contains Rubus suavissimus S. Lee extract, Houttuynia cordata Thunb. extract, Saururus chinensis Baill. extract, and Platycodon grandiflorum Nakai. Extract. The composition further contains Scutellariae baicalensis Labitae extract. A skin external composition for treating atopic dermatitis contains 0.01-20 weight% of the composition. A oral composition for treating atopic dermatitis contains 0.01-20 weight% of the composition.
PURPOSE:An aminoacid or a combination thereof with human serum albumin is added to an interferon aqueous solution, then freeze drying is effected to produce the titled preparation having actions of inhibiting virus proliferation and resisting tumors. CONSTITUTION:An aminoacid or a combination thereof with human serum albumin is added to an interferon aqueous solution. Then, preferably the pH is adjusted to 7.1+ or -0.1 using hydrochloric acid or sodium hydroxide, in order to increase the stability of interferon. The resultant solution is freeze-dried to give the objective interferon preparation. The amount of the aminoacid added is preferably 0.05-0.3w/v%, while the amount of human serum albumin is preferably 0.01-1w/v%. When the resultant preparation is dissolved, the use of glucose aqueous solution or the addition of glucose to a solution of the interferon in a physiological salt solution enables the interferon to be kept stable, even after dissolving.
The invention provides a traditional Chinese medicine extract for preventing Middle East respiratory syndrome (MERS). The traditional Chinese medicine extract is characterized by being prepared from the following components in parts by weight: 0 to 30 parts of gypsum (fine powder), 0 to 10 parts of radix scrophulariae, 0 to 8 parts of raw dioscorea rhizome, 0 to 4 parts of radix codonopsis, 0 to 60 parts of fresh lalang grass rhizome (washed and minced), 3 raw chicken yolks, 0 to 10 parts of honey-fried ephedra, 0 to 10 parts of almond, 0 to 10 parts of licorice, 0 to 10 parts of snakegourd fruit, 0 to 10 parts of semen lepidii, 0 to 10 parts of gypsum, 0 to 10 parts of radix peucedani, 0 to 10 parts of fritillaria cirrhosa, and 0 to 10 parts of bamboo leaf. The traditional Chinese medicine extract can be made into an environment-friendly and healthcare wet wipe having functions of sterilization, disinfection, deodorizing, and smell removing. The invention provides micromolecular group water and a preparation method thereof. During the preparation process, micromolecular group water is used to replace RO pure water. Compared with common wet wipes, the wet wipe can better relieve the skin pressure and improve the skin, and is more adaptive to the environment change; and the skin becomes more moist and lustrous. The wet wipe can be further made into a gauze mask, which contains the wet wipe as the chip and is capable of preventing MERS, and a spray agent for preventing MERS.